News
HLVX
13.61
-2.92%
-0.41
Weekly Report: what happened at HLVX last week (0429-0503)?
Weekly Report · 2h ago
Weekly Report: what happened at HLVX last week (0422-0426)?
Weekly Report · 04/29 09:03
HilleVax Becomes Oversold (HLVX)
NASDAQ · 04/25 16:27
Weekly Report: what happened at HLVX last week (0415-0419)?
Weekly Report · 04/22 09:02
Weekly Report: what happened at HLVX last week (0408-0412)?
Weekly Report · 04/15 09:02
Weekly Report: what happened at HLVX last week (0401-0405)?
Weekly Report · 04/08 09:02
Weekly Report: what happened at HLVX last week (0325-0329)?
Weekly Report · 04/01 09:02
Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), HilleVax, Inc (HLVX) and Cabaletta Bio (CABA)
TipRanks · 03/26 02:10
Weekly Report: what happened at HLVX last week (0318-0322)?
Weekly Report · 03/25 09:02
HilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued Valuation
HilleVax, Inc. Is developing a vaccine for the prevention of Norovirus-related acute gastroenteritis. Top line results from the phase 2/3 NEST-IN1 study, using HIL-214, are expected by mid-2024. The company is expected to be the first biotech to receive regulatory approval for a Norov virus-related illness.
Seeking Alpha · 03/22 17:55
HilleVax Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
Dow Jones · 03/21 10:40
HC Wainwright & Co. Reiterates Buy on HilleVax, Maintains $28 Price Target
Benzinga · 03/21 10:27
HilleVax, Inc’s HIL-214 Vaccine Candidate Promises Broad Protection Against Norovirus, Justifying Buy Rating
TipRanks · 03/21 10:16
HLVX Stock Earnings: HilleVax Beats EPS for Q4 2023
HilleVax reported earnings per share of -78 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was above the analyst estimate for EPS of -83 cents. Hillevax also reported results for the third quarter of 2018.
Investorplace · 03/21 01:53
Recap: HilleVax Q4 Earnings
HilleVax reported its Q4 earnings results on March 20. The company beat estimates by 6.0%. The company's revenue was down $0 from the same period last year. Hillevax is expected to announce its earnings on March 21, 2024.
Benzinga · 03/20 21:30
HilleVax GAAP EPS of -$0.78 beats by $0.05
HilleVax's Q4 GAAP EPS of -$0.78 beats by $0.05. As of December 31, 2022, the company had cash, cash equivalents and marketable securities of $303.5 million and $279.4 million. The increase was due to $107.8 million of net proceeds.
Seeking Alpha · 03/20 21:04
HilleVax files $500M mixed securities shelf
Seeking Alpha · 03/20 21:02
HilleVax Q4 2023 GAAP EPS $(0.78) Beats $(0.83) Estimate
Benzinga · 03/20 20:16
*HilleVax: Topline Data From NEST-IN1 Phase 2B Clinical Study of HIL-214 in Infants Expected in Mid-2024 >HLVX
Dow Jones · 03/20 20:04
*HilleVax 4Q Loss $37M >HLVX
Dow Jones · 03/20 20:01
More
Webull provides a variety of real-time HLVX stock news. You can receive the latest news about HilleVax, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About HLVX
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.